Targeting CD38 has demonstrated clinical activity in MM and other hematological malignancies expressing CD38, including acute myeloid leukemia (AML) and diffuse large B cell lymphoma (DLBCL)15. The gene discussed is CD38; the disease is diffuse large B-cell lymphoma.